{"nct_id":"NCT06312176","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","status_verified_date":"2025-10","start_date":"2024-04-14","start_date_type":"ACTUAL","primary_completion_date":"2027-07-11","primary_completion_date_type":"ESTIMATED","completion_date":"2031-04-12","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}